Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain.
Manuel BotanaMiguel CamafortRaquel Campuzano RuizAna CebriánManuel Gargallo FernándezHéctor David de PazJennifer Redondo-AntónEsther ArtimeSilvia Díaz-CerezoMiriam Rubio-de SantosPublished in: Advances in therapy (2024)
Physicians identified clinical, healthcare, and economic/administrative barriers that limit the use of GLP-1 RAs in people with T2D and high CV risk or established CVD in Spain, highlighting the importance of integrating these therapies according to clinical practice guidelines.